{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-026402","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.340897+00:00","generated_at":"2026-06-18T22:25:58.851892+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kiniksa reports Q4 net income $4.5M vs loss; ARCALYST revenue $122.5M in FY2022","bullets":["ARCALYST net product revenue $39.9M in Q4, $122.5M full-year 2022; FY2023 guidance $190-205M.","Total revenue $61.9M Q4, $220.2M full-year; license revenue from Roche/Genentech and Huadong.","Net income $4.5M Q4 vs loss $36.3M; full-year net income $183.4M includes $172.3M tax benefit.","Cash $190.6M, no debt; expects cash to fund operations into at least 2025.","KPL-404 Phase 2 RA trial advancing; efficacy data expected first half 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-026402","json":"https://secwatch.observer/filing/0001104659-23-026402.json","markdown":"https://secwatch.observer/filing/0001104659-23-026402.md","text":"https://secwatch.observer/filing/0001104659-23-026402.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465923026402/0001104659-23-026402-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465923026402/tm237813d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:25:58.851892+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04f5d67bbc345353ddecd1c052bc9482242a734a","claim":"Kiniksa Pharmaceuticals International, plc reported the fiscal year ended December 31, 2022 results: revenue Total revenue for the full-year 2022 was $220.2 million, net income Net income for the full-year 2022 was $183.4 million. Guidance reaffirmed.","evidence_excerpt":"On February 28, 2023, Kiniksa Pharmaceuticals, Ltd. issued a press release announcing financial results for the fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730430/000110465923026402/0001104659-23-026402-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"Total revenue for the full-year 2022 was $220.2 million"},{"label":"Net income","value":"Net income for the full-year 2022 was $183.4 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}